This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.
Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $63.83, marking a +0.42% move from the previous day.
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $62.19, moving +0.68% from the previous trading session.
Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.
Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPIN
Valneva (VALN) Reports Positive Data From COVID Vaccine Study
by Zacks Equity Research
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development
by Zacks Equity Research
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study
by Zacks Equity Research
AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug
by Zacks Equity Research
If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
by Zacks Equity Research
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker
by Zacks Equity Research
AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.